GW Pharmaceuticals plc announced that the company has appointed Julian Gangolli as President, North America and is also relocating its Chief Executive Officer, Justin Gover, to the United States. Mr. Gangolli was, from 2004 until April 2015, President of the North American Pharmaceutical division of Allergan Inc, with responsibility for a 1,400-person integrated commercial operation with sales exceeding $3.8 billion in 2014. Mr. Gangolli was an integral part of the executive management team that transformed Allergan into one of the leading specialty pharmaceutical companies in the U.S. Mr. Gangolli will join the company in June and is expected to be appointed to the company's board of directors. As President, North America Pharmaceuticals, Mr. Gangolli's responsibilities represented over 50% of Allergan's revenue, 60% of its profit, and over 60% of its year-on-year profit growth. He was responsible for four business units supporting each of the specialty areas of Ophthalmology/Optometry (Eye Care), Neurosciences, Urology and Medical Dermatology for the U.S. and Canada, each of which are considered category leaders in their respective therapeutic areas. In addition to his commercial responsibilities, Mr. Gangolli had responsibility for strategic planning, business development, research and product development planning for the North American division. Prior to his role as President, North America, Mr. Gangolli was Senior Vice President, U.S. Eye Care, at Allergan from 1998 to 2004.

The company is also continuing to expand its UK manufacturing and R&D operations in preparation for future commercialization as well as pipeline development.